Neoleukin Therapeutics, Inc. (NLTX)

Neoleukin Therapeutics to Present at Canaccord Genuity 42nd Annual Growth Conference

SEATTLE, Aug. 03, 2022 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc., “Neoleukin” (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, today announced that Jonathan Drachman, M.D., Chief Executive Officer, will present at the Canaccord Genuity 42nd Annual Growth Conference on Wednesday, August 10, 2022 at 1 p.m. Eastern. The webcast presentation can be accessed from the investors section of the Neoleukin website at ht

• 
  BiomX to Host Second Quarter 2022 Financial Results Conference Call and Webcast on August 10, 2022

  Business Wire
• TherapeuticsMD to Report Second Quarter 2022 Financial Results on August 15, 2022

  Business Wire

Neoleukin Therapeutics to Host Second Quarter 2022 Financial Results Conference Call and Webcast on August 9, 2022

SEATTLE, July 27, 2022 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc., "Neoleukin” (NASDAQ:NLTX), today announced it will report second quarter 2022 financial results on Tuesday, August 9, 2022 after the close of financial markets and then host a conference call and live audio webcast to discuss these results and provide a corporate update. Details of the event are as follows: Date: Tuesday, August 9, 2022 Time: 1:30 p.m. Pacific / 4:30 p.m. Eastern Toll-free: (800) 715-9871 Conference ID: 411

Neoleukin Therapeutics, Inc. (NASDAQ:NLTX) insider upped their holding by 6.7% earlier this year

Looking at Neoleukin Therapeutics, Inc.'s ( NASDAQ:NLTX ) insider transactions over the last year, we can see that...